Non-monotonic dynamics and crosstalk in signaling pathways and their implications for pharmacology

Currently, drug discovery approaches commonly assume a monotonic dose-response relationship. However, the assumption of monotonicity is increasingly being challenged. Here we show that for two simple interacting linear signaling pathways that carry two different signals with different physiological responses, a non-monotonic input-output relation can arise with simple network topologies including coherent and incoherent feed-forward loops. We show that non-monotonicity of the response functions has severe implications for pharmacological treatment. Fundamental constraints are imposed on the effectiveness and toxicity of any drug independent of its chemical nature and selectivity due to the specific network structure.

[1]  Q. Ouyang,et al.  Dose-Response Aligned Circuits in Signaling Systems , 2012, PloS one.

[2]  Yuhai Tu,et al.  The nonequilibrium mechanism for ultrasensitivity in a biological switch: Sensing by Maxwell's demons , 2008, Proceedings of the National Academy of Sciences.

[3]  Adam Yasgar,et al.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Petr Kuzmic,et al.  Practical Robust Fit of Enzyme Inhibition Data , 2004, Numerical Computer Methods, Part D.

[5]  C. Badiu.  Harrison's Principles of Internal Medicine 16th ed , 2005 .

[6]  Uri Alon,et al.  An Introduction to Systems Biology , 2006 .

[7]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[8]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[9]  Alvaro Puga,et al.  The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. , 2002, Molecular cancer therapeutics.

[10]  M. Grieser,et al.  Structure and stability of the negative hydrogen molecular ion. , 2011, Physical review letters.

[11]  E. Calabrese.  Getting the dose–response wrong: why hormesis became marginalized and the threshold model accepted , 2009, Archives of Toxicology.

[12]  Philipp M. Cromm,et al.  Small-molecule modulation of Ras signaling. , 2014, Nature chemical biology.

[13]  T. Hampton,et al.  "Promiscuous" anticancer drugs that hit multiple targets may thwart resistance. , 2004, JAMA.

[14]  Roland Seifert,et al.  Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. , 2013 .

[15]  A. deMello,et al.  Microfluidics: Analog-to-digital drug screening , 2012, Nature.

[16]  Simon K. Mencher,et al.  BMC Clinical Pharmacology BioMed Central Debate , 2005 .

[17]  Jason A. Papin,et al.  Reconstruction of cellular signalling networks and analysis of their properties , 2005, Nature Reviews Molecular Cell Biology.

[18]  A. Fliri,et al.  Cause-effect relationships in medicine: a protein network perspective. , 2010, Trends in pharmacological sciences.

[19]  Ruth Nussinov,et al.  Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review , 2012, Pharmacology & therapeutics.

[20]  A. Ramezanpour,et al.  Generating correlated networks from uncorrelated ones. , 2002, Physical review. E, Statistical, nonlinear, and soft matter physics.

[21]  Luhua Lai,et al.  Synergistic and Antagonistic Drug Combinations Depend on Network Topology , 2014, PloS one.

[22]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[23]  Monica L. Skoge,et al.  Receptor-receptor coupling in bacterial chemotaxis: evidence for strongly coupled clusters. , 2006, Biophysical journal.

[24]  C. Marshall,et al.  Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.

[25]  Robert Nadon,et al.  Statistical practice in high-throughput screening data analysis , 2006, Nature Biotechnology.

[26]  Juliane Junker,et al.  Enzyme Kinetics A Modern Approach , 2016 .

[27]  Filipe Tostevin,et al.  Multiplexing biochemical signals. , 2010, Physical review letters.

[28]  Shuji Ishihara,et al.  Cross talking of network motifs in gene regulation that generates temporal pulses and spatial stripes , 2005, Genes to cells : devoted to molecular & cellular mechanisms.

[29]  D. Margineanu.  Systems biology impact on antiepileptic drug discovery , 2012, Epilepsy Research.

[30]  Melvin E Andersen,et al.  Non-monotonic dose-response relationship in steroid hormone receptor-mediated gene expression. , 2007, Journal of molecular endocrinology.

[31]  H. Madhani,et al.  Principles of MAP kinase signaling specificity in Saccharomyces cerevisiae. , 2004, Annual review of genetics.

[32]  Uri Alon,et al.  The incoherent feed-forward loop can generate non-monotonic input functions for genes , 2008, Molecular systems biology.

[33]  J. Timmer,et al.  Design principles of a bacterial signalling network , 2005, Nature.

[34]  W-C Hwang,et al.  Identification of Information Flow‐Modulating Drug Targets: A Novel Bridging Paradigm for Drug Discovery , 2008, Clinical pharmacology and therapeutics.

[35]  Nigel D Goldenfeld,et al.  An Introduction to Systems Biology: Design Principles of Biological Circuits; Systems Biology: Properties of Reconstructed Networks , 2007 .

[36]  A. Ramezanpour,et al.  Investigation of a protein complex network , 2003, cond-mat/0304207.

[37]  W. D. Ronde,et al.  Multiplexing biochemical signals. , 2011 .

[38]  Reginald M. Atwater,et al.  The Merck Manual of Diagnosis and Therapy , 1950 .

[39]  S. Frantz.  Drug discovery: Playing dirty , 2005, Nature.

[40]  Andrew J. deMello,et al.  Analog-to-digital drug screening: Microfluidics , 2012 .

[41]  Madhusudan Natarajan,et al.  A global analysis of cross-talk in a mammalian cellular signalling network , 2006, Nature Cell Biology.

[42]  R. Germain,et al.  Navigating the network: signaling cross-talk in hematopoietic cells , 2009, Nature Immunology.

[43]  C. Hadley.  What doesn't kill you makes you stronger , 2003, EMBO reports.

[44]  A. Griffiths,et al.  High-resolution dose–response screening using droplet-based microfluidics , 2011, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Jiro Shimada,et al.  In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras–effector interaction , 2013, Proceedings of the National Academy of Sciences.

[46]  U. Alon.  Network motifs: theory and experimental approaches , 2007, Nature Reviews Genetics.

[47]  F. Tostevin,et al.  Feed-forward loops and diamond motifs lead to tunable transmission of information in the frequency domain. , 2012, Physical review. E, Statistical, nonlinear, and soft matter physics.

[48]  N. Wingreen,et al.  A dynamic-signaling-team model for chemotaxis receptors in Escherichia coli , 2010, Proceedings of the National Academy of Sciences.

[49]  B. Palsson,et al.  Towards genome-scale signalling-network reconstructions , 2010, Nature Reviews Genetics.

[50]  K A Thayer,et al.  Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[51]  N. Ellison,et al.  The Merck Manual of Diagnosis and Therapy. 17th ed. , 1999 .

[52]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.